Futibatinib

Phase 3

Zymeworks Inc. (ZYME)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

ZYMEPhase 3$1.9B

Futibatinib Phase 3 Est. Readout

Futibatinib• Biliary Tract Neoplasms800

Jun 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Biliary Tract Neoplasms

View Full Landscape

Drug Information

Target Indication

Biliary Tract Neoplasms

Clinical Trial

NCT05615818

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/4/2023

Lytgobi

Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Conditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ZYME

Zymeworks Inc.

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

ZW25Phase 2

Endometrial Cancer

ZanidatamabPhase 2

Breast Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts